By Lisa Kerner
Charlotte, N.C., Aug. 1 - VeraLight, Inc. said it completed a $17.5 million round of series B financing.
Proceeds will be used to complete development, testing and introduction of the VeraLight Scout diabetes screening system.
New investor Psilos Group led the financing round, joined by CMEA Ventures and previous investors vSpring Capital, Wasatch Venture Fund, The Dow Chemical Co. and the Southern Ute Growth Fund.
Lisa Suennen, managing director of Psilos Group, and David Collier, managing director of CMEA Ventures, will join VeraLight's board of directors.
VeraLight is a privately held medical instrumentation company based in Albuquerque, N.M.
| Issuer: | VeraLight, Inc.
|
| Issue: | Series B financing
|
| Amount: | $17.5 million
|
| Investors: | Psilos Group (lead), CMEA Ventures, vSpring Capital, Wasatch Venture Fund, The Dow Chemical Co. and the Southern Ute Growth Fund.
|
| Announcement date: | Aug. 1
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
